Trazimera

Trazimera Use In Pregnancy & Lactation

trastuzumab

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma
Full Prescribing Info
Use In Pregnancy & Lactation
Women of childbearing potential: Women of childbearing potential should be advised to use effective contraception during treatment with TRAZIMERA and for 7 months after treatment has concluded (see Pharmacology: Pharmacokinetics under Actions).
Pregnancy: Reproduction studies have been conducted in Cynomolgus monkeys at doses up to 25 times that of the weekly human maintenance dose of 2 mg/kg trastuzumab intravenous formulation and have revealed no evidence of impaired fertility or harm to the foetus. Placental transfer of trastuzumab during the early (days 20-50 of gestation) and late (days 120-150 of gestation) foetal development period was observed. It is not known whether trastuzumab can affect reproductive capacity. As animal reproduction studies are not always predictive of human response, trastuzumab should be avoided during pregnancy unless the potential benefit for the mother outweighs the potential risk to the foetus.
In the post-marketing setting, cases of foetal renal growth and/or function impairment in association with oligohydramnios, some associated with fatal pulmonary hypoplasia of the foetus, have been reported in pregnant women receiving trastuzumab. Women who become pregnant should be advised of the possibility of harm to the foetus. If a pregnant woman is treated with TRAZIMERA, or if a patient becomes pregnant while receiving TRAZIMERA or within 7 months following the last dose of TRAZIMERA, close monitoring by a multidisciplinary team is desirable.
Breast-feeding: A study conducted in lactating Cynomolgus monkeys at doses 25 times that of the weekly human maintenance dose of 2 mg/kg trastuzumab intravenous formulation demonstrated that trastuzumab is secreted in the milk. The presence of trastuzumab in the serum of infant monkeys was not associated with any adverse effects on their growth or development from birth to 1 month of age. It is not known whether trastuzumab is secreted in human milk. As human IgG1 is secreted into human milk, and the potential for harm to the infant is unknown, women should not breast-feed during TRAZIMERA therapy and for 7 months after the last dose.
Fertility: There is no fertility data available.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in